Dr Andrew Gaya is a Consultant Clinical Oncologist based at Guy's and St. Thomas' NHS Foundation Trust.
Dr Gaya originally qualified at St George’s Hospital Medical School (University of London) where he was awarded a distinction and several academic prizes. He trained in Clinical Oncology at Imperial College and St Bartholomew’s Hospital and subsequently undertook a Cancer Research UK MD Fellowship at University College London.
Dr Gaya treats solid tumours using chemotherapy, radiotherapy, and biological therapy – His main focus is on colorectal cancer, cancers of the oesophagus, stomach, pancreas, liver, and lung cancer. Dr Gaya’s main research interest is in the area of functional cancer imaging, where he is looking for ways to assess response to treatment much earlier and techniques for assessing blood flow and oxygen levels within cancers.
He is also heavily involved with the implementation of the latest radiotherapy techniques such as IMRT, IGRT and Tomotherapy, combining targeted or anti-vascular drugs with radiotherapy, and stereotactic body radiosurgery. He is one of the first UK doctors to use the CyberKnife stereotactic body radiosurgery unit. He has published widely in peer-reviewed journals, and is currently lead clinical oncologist for audit and clinical governance at Guy’s and St Thomas’ NHS Foundation Trust.
Amit Bahl is Consultant Clinical Oncologist and Clinical Director based at The Bristol Haematology & Oncology Centre.
Dr Bahl has a special interest in breast and urological cancers.
He has led and developed the prostate brachytherapy service at Bristol. He has been an expert adviser to NICE for the technology appraisal on new drugs and an external service reviewer. He has been awarded the fellowship of the Royal College of Physicians.
Dr Bahl is a current member of the National Cancer Research Institute for prostate and bladder cancer, and has supervised several research projects. He has previously been in the NCRI Renal clinical studies group. He is an Executive Committee member of the British Uro-oncology group. Dr Bahl is actively involved in research into breast, prostate and bladder cancers, participates in clinical trials and regularly publishes articles and has several presentations at national and international meetings.
In 2012, Dr Bahl was awarded the Cochrane Shanks Jalil Professorship by the Royal College of Radiologists, London.
Dr Amir Montazeri is a Consultant Clinical Oncologist at The Clatterbridge Centre for Oncology.
Dr Montazeri studied medicine in Tehran and completed his clinical oncology training on the Wirral, UK, where he remains today.
He specialises in colorectal and urological cancers, giving treatment with both chemotherapy and radiotherapy. He also has an interest in Selective Internal Radiation Therapy.
Dr Montazeri is a member of Royal College of Physicians and Surgeons of Glasgow, a Fellow of Royal College of Radiologists and a member of British Uro-oncology Group.
Mr Amar Deshpande is a Consultant Breast Surgeon based at Wigan Wrightington and Leigh NHS Trust.
Mr Deshpande completed his basic surgical training in B Y L Nair Hospital (affiliated to University of Bombay), Mumbai. He was trained as a Specialist Registrar in General Surgery subspecialty Breast Surgery at West Midlands Deanery, Birmingham. He completed his fellowship in breast reconstructive and cosmetic surgery (Oncoplastic Fellowship) and was appointed Consultant Breast Surgeon at Wrightington Wigan and Leigh NHS Foundation Trust in January 2010 and is also an examiner for The Royal College of Physicians and Surgeons of Glasgow for MRCS exams.
Mr Deshpande is an Oncoplastic Breast and General Surgeon in Lancashire and also lead clinician in breast surgery. He deals with all aspects of breast problems including management of benign breast problems, breast cancer and breast reconstruction (Latissimus Dorsi, TRAM, implant based with or without biological mesh) and therapeutic mammoplasty. He also performs cosmetic breast surgery (breast augmentation, breast reduction, mastopexy, nipple reconstruction, nipple areolar tattooing). He performs lipotransfer for correction of deformities after breast surgery and for natural breast augmentation.
Dr Lip Lee is a Consultant Clinical Oncologist based at The Christie NHS Foundation Trust in Manchester.
Dr Lee graduated from University of Melbourne, Australia in 1997. From there he started his general medical training in the UK.
He started working in oncology in the Christie, Manchester in 2000, after completing his MRCP. During the course of his training in oncology at the Christie, he also visited the MD Anderson cancer centre and William Beaumont Hospital in the USA to develop further specific technical skills in IMRT and SABR.
He is one of the clinical leads who developed stereotactic lung radiotherapy for lung cancer for the first time in the North West and is constantly involved with new developments in IMRT for head & neck and lung cancers.
Dr Lee was on the examination panel for Royal College of Radiologists, UK and Manchester medical school, and is currently the ‘Training Programme Director’ for the oncology training in the North West Region.
He speaks numberous anguages including English, Cantonese, Mandarin, Hakka, and Indonesian.
Professor Peter Selby is a Professor of Medical Oncology and Consultant Physician at St James’s University Hospital, the St James’s Institute of Oncology and Professor of Cancer Medicine at the University of Leeds.
Prof Selby has worked in cancer research and cancer care since 1976. After completing a Natural Sciences degree at the University of Cambridge in 1971, he undertook undergraduate medical training at King’s College Hospital in London and then medical and oncological training posts in Kings College Hospital, University College Hospital and the Royal Marsden Hospital in London and in the Princess Margaret Hospital and Ontario Cancer Institute in Toronto. He was a clinical research fellow at the Institute for Cancer Research and Royal Marsden and became a Consultant and Senior Lecturer there in 1984.
He was appointed Fellow of the Academy of Medical Sciences in 1998, and awarded a CBE in 2001 for services to cancer research and cancer care. Peter is President of the Association of Cancer Physicians (2007-) and won the Pfizer Excellence in Oncology Lifetime Achievement award in 2007. He is an Honorary Life member of the British Psychosocial Oncology Society and remains a co-investigator on patient reported outcome research into prostate cancer and chemotherapy toxicity. In 2010 he was appointed a Senior Investigator of the National Institute for Health Research. In 2011 he was awarded a DSc.
As Director/Lead Clinician of the NHS Leeds Cancer Centre (1997-2003) he organised specialised multidisciplinary care for cancer patients and led the development of excellent facilities for patients. More recently (2013) he helped to initiate an Integrated Cancer Service to address the need for better access to care and address inequalities. He was Consultant Advisor on Cancer Services to the Chief Medical Officer in England (Sir Kenneth Calman) (1993-2000) and is President and Chief Executive of the European Cancer Concord (2014-). In both latter roles he sought to develop and implement evidence-based plans to improve outcomes for cancer patients and tackle cancer inequalities. Peter is a Trustee of Cancer Research UK (2012-), Chairman of the Cancer Research UK Public Policy Advisory Group and a member of the Cancer Research UK Research Strategy Committee.
Professor John Radford is a Consultant Medical Oncologist based at The Christie NHS Foundation Trust.
Professor Radford is Director of Research at the Christie, Clinical Lead for the Manchester Cancer Research Centre (MCRC) and Clinical Academic Section Lead for cancer in the Manchester Academic Health Science Centre (MAHSC).
Professor Radford is also the Teenage Cancer Trust Professor of Teenage and Young Adult Cancer at the University of Manchester and Director of Research.
His research interests are focused on developing and testing new ways of treating lymphoma and monitoring the effectiveness of these treatments using novel biomarkers. He is also interested in studying the late effects of chemotherapy on fertility, heart function and the risk of second cancers and is investigating how best to prevent or minimise the impact of these in people cured of lymphoma. He is an advocate of patient choice in health care systems and believes that patient organisations have an important role in terms of providing information and support and influencing the development of national policy.
Dr Fiona Blackhall is a Consultant Medical Oncologist based at The Christie Foundation NHS Trust in Manchester.
She is Lung Cancer Research Group Lead at Manchester Cancer Research Centre and the Lung Disease Group Chair at The Christie.
Dr Blackhall was a undergraduate at St Andrews and Manchester Universities. She undertook an intercalated BSc in St Andrews in the laboratory of Dr Peter Bryant in the field of radiobiology and DNA repair, and commenced Medical Oncology training at The Christie Hospital in 1995.
Dr Blackhall's overall objective is to contribute clinically relevant lung cancer research to improve outcomes for lung cancer patients and ultimately to make lung cancer a less common and less deadly disease.
Dr Fiona Blackhall holds Memberships of Committees and Professional Bodies on:
The British Thoracic Oncology Group; European Thoracic Oncology Platform; European Society of Medical Oncology (Faculty Member); American Society of Clinical Oncology (Faculty Member; Advanced Disease Subgroup member, NCRI Lung Clinical Studies Group; and The International Association for the Study of Lung Cancer (Faculty Member)
Professor Timothy Perren is a Consultant Medical Oncologist based at St James's University Hospital, part of The Leeds Teaching Hospitals NHS Trust.
Prof Perren trained in general medicine in London and Stoke on Trent. His oncology training was in Birmingham and at the Royal Marsden Hospital, London. He was appointed consultant medical oncologist at St James's Hospital in Leeds in January 1990. He specialises in the non-surgical treatment of cancers using chemotherapy, hormonal therapy and the new targeted molecular therapies. Prof Perren believes that it is important to take into account the individual needs and situation of each patient and to involve the patient and their family closely in the development of a treatment plan.
Professor Perren specialises in the treatment of breast cancer and gynaecological cancers, including ovarian cancer, cervical cancer and endometrial cancer. He provides treatment for newly diagnosed patients, as well as for those with recurrent or metastatic disease and has gained a high degree of knowledge and understanding of difficult constellation of symptoms that can often accompany cancer and its treatment. Professor Perren’s philosophy of patient care puts the patient at the centre of treatment planning. He believes in discussing all options of treatment before finally coming up with a solution that is best for the individual concerned.
Professor Perren is a member of various organisations and groups including: fellow of the Royal College of Physicians; He is former Chair of the Joint Colleigate Council for Oncology and Joint Specialty Committee for Medical Oncology at the Royal College of Physicians; He is a member of the American Society of Clinical Oncology; European Society of Medical Oncology; Association of Cancer Physicians; Yorkshire Cancer Network Breast Group; Yorkshire Cancer Network Gynaecology Group;National Cancer Research Institute Gynaecological Cancer Clinical Studies Group, and the UK Breast Cancer Intergroup.